Uterine Cervical Neoplasms Clinical Trial
Official title:
Low-Cost Molecular Cervical Cancer Screening Study
Verified date | December 20, 2010 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Background:
- Low-cost molecular human papillomavirus (HPV) testing may offer a more robust alternative
to Pap smears and visual inspection for cervical cancer screening of underserved women. Two
low-cost molecular tests for human HPV, the HPV E6 Test and the careHPV test, have been
developed to detect cervical cancer by testing for HPV DNA. These tests take between 2 and 3
hours to run and may provide point-of-care (diagnostic testing at or near the site of patient
care) testing for HPV. Researchers are interested in evaluating both tests to determine the
best strategy for HPV testing of women who live in rural or underserved areas that have a
high prevalence of cervical cancer diagnoses.
Objectives:
- To evaluate the clinical performance of the HPV E6 Test and careHPV in detecting
cervical cancer and precancerous lesions.
- To evaluate the best low-cost test or combination of tests for women who have been
referred for cervical cancer screening or treatment.
- To compare the clinical performance of self-collected specimens versus
clinician-collected specimens in detecting cervical cancer and precancerous lesions.
Eligibility:
- Women between 25 and 65 years of age who live in rural China.
Design:
- This study involves an initial testing visit and a 1-year followup visit for a high-risk
subgroup.
- Participants will have the HPV E6 test, careHPV, and a visual inspection test for
cervical cancer. For comparison, participants will also have the standard HPV test
approved by the U.S. Food and Drug Administration.
- Participants who test positive for HPV on any of the above tests will also have
colposcopy to collect samples of cervical tissue for further study.
- A random sample of women who test negative for HPV will also have colposcopy.
Participants may also have biopsies if there is visual evidence of cervical
abnormalities.
- At the 1-year followup visit, participants in the high-risk subgroup will have the same
tests as in the previous visit..
Status | Completed |
Enrollment | 7500 |
Est. completion date | December 20, 2010 |
Est. primary completion date | |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 25 Years to 65 Years |
Eligibility |
- INCLUSION CRITERIA: 1. have not been previously diagnosed with cervical cancer 2. have a cervix 3. are not pregnant 4. are physically able to undergo routine cervical cancer screening 5) are able to provide informed consent - We will not exclude women if they have had previous cervical cancer screening because we assume that even if a few women have been screened for cervical cancer, the quality of cytology screening was very poor. EXCLUSION CRITERIA: 1) are not married AND report never having had sexual intercourse 2) have had a total hysterectomy 3) have a history of cervical cancer 4) are physically or mentally unable to undergo routine cervical cancer screening or unable to provide informed consent. 5) are pregnant or have been pregnant in the last month -Women who are currently menstruating at the time of enrollment will be deferred from participating, and will become eligible to participate 7-14 days after menstruation has ended. The menstruating women will be advised to return for the screening 7 to 14 days after their menstrual period has concluded. |
Country | Name | City | State |
---|---|---|---|
China | CICAMS | Beijing | Beijing |
United States | PATH | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States, China,
Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 2006 May;110(5):525-41. Review. — View Citation
Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10. Epub 2006 Jun 23. Review. — View Citation
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT01373723 -
Economic Evaluation of Three Populational Screening Strategies for Cervical Cancer
|
N/A | |
Terminated |
NCT01194609 -
A Pilot Study of Radiation-Immune Cell Combination Therapy in Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02808832 -
An HPV Vaccine Provider Intervention in Safety Net Clinics
|
N/A | |
Terminated |
NCT01234480 -
Intended Use Study of the BD SurePath Plus™ Pap
|
||
Terminated |
NCT01075412 -
FLT PET Imaging for Cervical Cancer
|
Phase 2 | |
Completed |
NCT01014026 -
Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention
|
Phase 3 | |
Completed |
NCT02865889 -
Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications
|
N/A | |
Completed |
NCT00377845 -
Cervix Cytological Screening - Comparison of Tampon Self-Test and the Routine Smear.
|
Phase 0 | |
Recruiting |
NCT05531981 -
Detection of Minimal Residual Disease Based on HPV ctDNA in Cervical Cancer
|
||
Recruiting |
NCT05393440 -
First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT02866006 -
Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT02320578 -
2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial
|
N/A | |
Completed |
NCT03270995 -
Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study
|
N/A | |
Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
Not yet recruiting |
NCT05065853 -
Urinary and Vaginal HPV Testing in Cervical Cancer Screening
|
||
Completed |
NCT01717391 -
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
|
Phase 2 | |
Active, not recruiting |
NCT04947605 -
Epidemiological Landscape of Cervical Cancer in Latin America
|
||
Recruiting |
NCT06124040 -
Sexual Function, Coping and Dyadic Coping in Patients With Cervical Cancer
|